Wednesday
SESSION 31: ADVANCES IN MEDICAL TREATMENTS, ANTI-ATHEROGENIC DRUGS AND CARDIAC AND CORONARY ARTERY RISK EVALUATION IN PATIENTS WITH VASCULAR DISEASE
Location: Grand Ballroom West, 3rd Floor
Moderators:Ido Weinberg, MD, MSc / Caron B. Rockman, MD  
SESSION 31 SCHEDULE
6:40 AM - 6:45 AM What Is Currently The Best Way To Assess Cardiac Risk In Open Vascular Surgery Patients; In Endovascular Treatment Patients
  Presenter(s):Peter Henke, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
6:46 AM - 6:51 AM Fractional Flow Reserve From Coronary CT (FFRCT): What Is It, And It Is A Better Way To Guide Coronary Artery Revascularization
  Presenter(s):Gregg W. Stone, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
6:52 AM - 6:57 AM Value Of Non-Invasive FFRCT In Decreasing Cardiac Complications In Patients Undergoing Lower Extremity Revascularization (Bypasses) And CEAs: It Allows High Risk Asymptomatic Patients To Be Detected Proactively And Treat Better
  Presenter(s):Christopher K. Zarins, MD / Dainis K. Krievins, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
6:58 AM - 7:03 AM Improvements In And What Is Coming In Medical Treatment To Prevent Death And Complications From Arteriosclerosis: Update On PCSK-9 Inhibitors Including Inclisiran, Ezetembe, Anti-Inflammatory Drugs And Treating High Lp(a) Levels
  Presenter(s):Michael R. Jaff, DO  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:04 AM - 7:09 AM DEBATE: Adherence To Statin Therapy With Attention To Increase Dosage Of High Potency Statins (Atorvastatin And Ruvostatin) Boosts Survival And Is Valuable In The Elderly (> 75): Adverse Effects Are Rare
  Presenter(s):Richard Bulbulia, MA MD FRCS  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:10 AM - 7:15 AM DEBATE: Statins Are Not A Miracle Drug And Have Been Overvalued: They Have Unrecognized Harmful Effects As Does Excessive Lowering Of LDL Cholesterol (LDL-C): Have We Been Misled And By Whom
  Presenter(s):Sherif A.H. Sultan, MD, PhD, FRCS, EBQS-VASC  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:16 AM - 7:21 AM Highlights Of The New AHA Guidelines For Management Of Cholesterol Levels: What LDL-C Levels Should We Strive For In Our Vascular Patients: Why Are Non-HDL Levels A Better Indicator Of Atherosclerotic Risk Than LDL-C Levels
  Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC   
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:22 AM - 7:27 AM Value Of Lipid Lowering For Treating Plaques In Coronary And Other Arteries: Best Drug Combination And Benefit Of PCSK-9 Inhibitors: How Low Should LDL-C Be Driven: Can Plaques Be Made Smaller And Less Dangerous
  Presenter(s):Ron Waksman, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:28 AM - 7:33 AM Current Value Of Antithrombotic And Antiplatelet Therapy In Vascular Patients: What Drugs Should They Be On When And Why: The COMPASS RCT Shows That Low Dose Rivaroxaban And Aspirin Decreases Death, Stroke And MI In Vascular Patients: What About Aspirin Alone
  Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC   
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:34 AM - 7:39 AM How To Detect Vulnerable Plaque (Lipid Rich Plaque [LRP]) And Mortality Risk With New Infrared Spectroscopy (NIRS); How Does It Work: What Can Be Done About LRPs
  Presenter(s):Ron Waksman, MD  
Location: Grand Ballroom West, 3rd Floor
  View Slides in PDF      
7:40 AM - 7:47 AM Panel Discussion
END OF SESSION 31
previous next